Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER
Document Type and Number:
WIPO Patent Application WO/2022/138944
Kind Code:
A1
Abstract:
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and/or prophylactic effect on SWI/SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and/or preventing cancer and contains an CBP/P300 inhibitor, can be provided. The cancer may be SWI/SNF complex-dysfunction cancer. The SWI/SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2/A4-deficient cancer.

More Like This:
JP2015525785Vaccine based on peptide EGFRvIII sequence for tumor treatment
WO/1997/045105COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS
JP2001517624INDUSTRIAL APPLICABILITY: Nicotine composition and method for formulating the nicotine composition.
Inventors:
OGIWARA HIDEAKI (JP)
SASAKI MARIKO (JP)
Application Number:
PCT/JP2021/048330
Publication Date:
June 30, 2022
Filing Date:
December 24, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
NAT CANCER CT (JP)
SUMITOMO PHARMA CO LTD (JP)
International Classes:
A61K45/00; A61K31/40; A61K31/404; A61K31/407; A61K31/415; A61K31/416; A61K31/4166; A61K31/417; A61K31/4178; A61K31/4184; A61K31/423; A61K31/426; A61K31/427; A61K31/437; A61K31/4427; A61K31/4433; A61K31/444; A61K31/454; A61K31/4545; A61K31/472; A61K31/496; A61K31/4985; A61K31/55; A61K31/553; A61K31/662; A61K31/7088; A61K31/7105; A61K31/713; A61P35/00; A61P35/02; A61P43/00; C07D207/16; C07D209/12; C07D213/74; C07D217/26; C07D231/12; C07D233/74; C07D263/52; C07D277/34; C07D401/04; C07D413/04; C07D417/04; C07D471/04; C07D487/04; C07D491/048; C07D495/04; C07D498/04; C12N9/10; C12N9/99; C12N15/113; C12N15/54
Domestic Patent References:
WO2016044770A12016-03-24
WO2016044771A12016-03-24
WO2016044777A12016-03-24
WO2018235966A12018-12-27
WO2019111980A12019-06-13
WO2019049061A12019-03-14
WO2019161162A12019-08-22
WO2019161157A12019-08-22
WO2019201291A12019-10-24
WO2020108500A12020-06-04
WO2019055877A12019-03-21
WO2019191667A12019-10-03
WO2019195846A12019-10-10
WO2020092907A12020-05-07
WO2020176558A12020-09-03
WO2020198567A12020-10-01
WO2019118973A12019-06-20
Foreign References:
JP2017529358A2017-10-05
JP2019516759A2019-06-20
JP2017537100A2017-12-14
JP2019537571A2019-12-26
JP2019508496A2019-03-28
CN110862383A2020-03-06
Attorney, Agent or Firm:
KOMATANI, Takeshi (JP)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: PRODUCTION METHOD FOR NON-HUMAN MODEL ANIMAL WITH MENTAL DISORDER OR NEUROLOGICAL DISORDER, SAID NON...

Next Patent: METHOD FOR CONTROLLING HARMFUL ANNELID USING NATURAL PYRETHRIN